The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Gut

• Publication date

  2011-02-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gut.2010.226548PMID 21317177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natalizumab for the treatment of Crohn’s disease

  2010cited by this paper
• CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis.

  2010cited by this paper
• Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody

  2009influential reference
• Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

  2009cited by this paper
• W1042 Mechanistic Population Pharmacokinetics (PK) Model of PF-00547659, a Fully Human IgG2 Anti-MAdCAM Antibody, in Ulcerative Colitis Patients: Results of a First in Human (Fih) Study

  2009cited by this paper
• TNFα blockade in human diseases : An overview of efficacy and safety

  2008cited by this paper
• Drug Safety Evaluation

  2008cited by this paper
• The effects of natalizumab on the innate and adaptive immune system in the central nervous system.

  2008cited by this paper
• Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

  2008cited by this paper
• Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

  2008cited by this paper
• TNFalpha blockade in human diseases: an overview of efficacy and safety.

  2008cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• Immune surveillance in multiple sclerosis patients treated with natalizumab

  2006cited by this paper
• Natalizumab effects on immune cell responses in multiple sclerosis

  2006cited by this paper
• Fatalities in natalizumab treatment – a ‘no go’ for leukocyte recirculation approaches?

  2006cited by this paper
• Antisense therapy of MAdCAM‐1 for trinitrobenzenesulfonic acid‐induced murine colitis

  2006cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM‐1 and C‐C chemokine mLARC/CCL20 in DSS‐induced mice colitis

  2005cited by this paper
• Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Natalizumab induction and maintenance therapy for Crohn's disease.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

  2005cited by this paper
• Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

  2005cited by this paper
• Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis

  2004cited by this paper
• Natalizumab for active Crohn's disease.

  2003cited by this paper
• A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrin

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease

  2001cited by this paper
• MAdCAM mediates lymphocyte-endothelial cell adhesion in a murine model of chronic colitis.

  2001cited by this paper
• A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

  2001cited by this paper
• Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1.

  2000cited by this paper
• Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats.

  2000cited by this paper
• Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.

  1997cited by this paper
• Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.

  1997cited by this paper
• Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo.

  1994cited by this paper
• α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1

  1993cited by this paper
• Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

  1993cited by this paper
• Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain

  1992cited by this paper
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Safety and efficacy of ontamalimab in inflammatory bowel disease: A systematic review and dose- response meta-analysis

  2026cites this paper
• Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach

  2024cites this paper
• Efficacy and Safety of Etrolizumab in the Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  2024cites this paper
• Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.

  2023cites this paper
• Differential Effects of Anti-TNFα and Anti-α4β7 Drugs on Circulating Dendritic Cells Migratory Capacity in Inflammatory Bowel Disease

  2022cites this paper
• Screening of ulcerative colitis biomarkers and potential pathways based on weighted gene co-expression network, machine learning and ceRNA hypothesis

  2022cites this paper
• Controlling in and out – the future of interfering with immune cell trafficking in inflammatory bowel disease

  2022cites this paper
• Yoga Therapy on Digestive Function in Inflammatory Bowel Disease

  2021cites this paper
• Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy

  2021cites this paper
• Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

  2021cites this paper
• Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents

  2021cites this paper
• Targeting Leukocyte Trafficking in Inflammatory Bowel Disease

  2021cites this paper
• Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

  2021cites this paper
• Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions

  2020cites this paper
• Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

  2020cites this paper
• 4）病態からみえてきた炎症性腸疾患治療―現在そして未来にむけて―

  2020cites this paper
• Tunicamycin induced endoplasmic reticulum stress in the small intestine

  2020cites this paper
• Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis.

  2020cites this paper
• Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More

  2020cites this paper
• Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?

  2019cites this paper
• Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease

  2019cites this paper
• Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies

  2019cites this paper
• Anti-MADCAM therapy for ulcerative colitis

  2019cites this paper
• Interrogating host immunity to predict treatment response in inflammatory bowel disease

  2019cites this paper
• Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.

  2019cites this paper
• Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD

  2019cites this paper
• Mechanisms of Disease: Inflammatory Bowel Diseases.

  2019cites this paper
• Monoclonal Antibodies for Immune System-Mediated Diseases

  2019cites this paper
• Anti-integrin Agents in IBD: Efficacy and Risk of Complications

  2018cites this paper
• Development of Novel Therapies for the Treatment of Inflammatory Bowel Disease

  2018cites this paper
• Pharmacotherapy of ulcerative colitis – current status and emerging trends

  2018cites this paper
• Emerging Therapies for Inflammatory Bowel Disease

  2018cites this paper
• Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

  2018cites this paper
• A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

  2018cites this paper
• PF-00547659 for the treatment of Crohn’s disease and ulcerative colitis

  2018cites this paper
• α4β7 integrin inhibitors: a patent review

  2018cites this paper
• Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

  2017cites this paper
• Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set

  2017cites this paper
• Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.

  2017cites this paper
• Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

  2017cites this paper
• Emerging treatments for ulcerative colitis: a systematic review

  2017cites this paper
• Novel Targeted Therapies for Inflammatory Bowel Disease.

  2017cites this paper
• High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients

  2017cites this paper
• Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound

  2017cites this paper
• Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era.

  2017cites this paper
• Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation.

  2017cites this paper
• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cites this paper
• Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

  2017cites this paper
• Targeting Specific Immunologic Pathways in Crohn's Disease.

  2017cites this paper
• Novel treatments for inflammatory bowel disease

  2017cites this paper
• Update on the Use of Biologic Therapy in Ulcerative Colitis

  2017cites this paper
• Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions

  2017cites this paper
• Integrins: Integrating the Biology and Therapy of Cell-cell Interactions.

  2017cites this paper
• IBD Therapies: Coming Attractions

  2017cites this paper
• New Non-anti-TNF-α Biological Therapies for the Treatment of Inflammatory Bowel Disease

  2017cites this paper
• Mucosal immunology and imaging in early Inflammatory Bowel Disease

  2017cites this paper
• Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rHUMab Beta 7), Anti-MAdCAM

  2017cites this paper
• Therapeutic Targets in Infl ammatory Bowel Disease : Current and Future

  2016cites this paper
• Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence

  2016cites this paper
• The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn's disease

  2016cites this paper
• The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews

  2016cites this paper
• Leukocyte Trafficking to the Small Intestine and Colon.

  2016cites this paper
• Immune Based Therapies for Inflammatory Bowel Disease

  2016cites this paper
• Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.

  2016cites this paper
• Therapeutic Targets in Inflammatory Bowel Disease: Current and Future

  2016cites this paper
• Glucocorticoids Suppress CCR9-Mediated Chemotaxis, Calcium Flux, and Adhesion to MAdCAM-1 in Human T Cells

  2016cites this paper
• Will novel oral formulations change the management of inflammatory bowel disease?

  2016cites this paper
• Emerging therapeutic targets and strategies in Crohn’s disease

  2016cites this paper
• Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease

  2016cites this paper
• Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

  2016influential citation
• Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study

  2016cites this paper
• The unusual suspects—innate lymphoid cells as novel therapeutic targets in IBD

  2015cites this paper
• Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.

  2015cites this paper
• Medical Therapy of Active Ulcerative Colitis

  2015cites this paper
• Next-Generation Therapeutics for IBD

  2015cites this paper
• Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

  2015cites this paper
• Ulcerative Colitis: Update on Medical Management

  2015cites this paper
• Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

  2015cites this paper
• The Current State of the Inflammatory Bowel Disease Drug Pipeline: A Promising Time

  2015cites this paper
• Medical Therapy: The Future

  2015cites this paper
• Novel Drug Therapies for the Treatment of Crohn's Disease

  2015cites this paper
• Chapter 40 - Lymphocyte Trafficking to Mucosal Tissues

  2015cites this paper
• [Targeting and role of α4β7 integrin in the pathophysiology of IBD and HIV infection].

  2015cites this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cites this paper
• Neue Biologika für die Behandlung chronisch-entzündlicher Darmerkrankungen

  2014cites this paper
• New Strategies for Treatment of Inflammatory Bowel Disease

  2014cites this paper
• Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.

  2014cites this paper
• Mucosal Addressin Cell Adhesion Molecule-1 of Rhesus Macaques: Molecular Cloning, Expression, and Alteration After Viral Infection

  2014cites this paper
• Biological therapy for ulcerative colitis

  2014cites this paper
• Vedolizumab for the treatment of ulcerative colitis

  2014cites this paper
• Editorial: The IBD Drug Pipeline—Ready to Deliver?

  2014cites this paper
• Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.

  2014influential citation
• New Drugs on the Horizon for IBD

  2014cites this paper
• Targeting Integrins and Adhesion Molecules to Combat Inflammatory Bowel Disease

  2014influential citation
• Therapy of inflammatory bowel disease: what to expect in the next decade

  2014cites this paper
• Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis

  2014cites this paper
• Review article: anti‐adhesion therapies for inflammatory bowel disease

  2014cites this paper
• Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target

  2014cites this paper
• Advances in IBD genetics

  2014cites this paper
• Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

  2014cites this paper